SCHEMBL220061

SCHEMBL220061

FCC1CNCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL220060 1.00
SCHEMBL3316452 1.00
Hydrochloric Acid SCHEMBL27617015 0.97
Hydrochloric Acid SCHEMBL7813735 0.97 LTA4H (0.34)
Acetic Acid SCHEMBL30701580 0.85 SLC6A1 (0.33)
Acetic Acid SCHEMBL30701581 0.85 SLC6A1 (0.33)
SCHEMBL14715748 0.80
SCHEMBL336761 0.74
SCHEMBL2276644 0.74
SCHEMBL6223573 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US claimed
US-5210193-A Bactericide AMERICAN CYANAMID COMPANY (US) 1993-05-11 US claimed
JP-1070484-A None JP disclosed
JP-1070483-A None JP disclosed
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 US disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 US disclosed
EP-4395892-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
CN-118302426-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-07-05 CN disclosed
US-20240199607-A1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LIMITED (GB) 2024-06-20 US disclosed
US-11866428-B2 Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (GB) 2024-01-09 US disclosed
WO-2023034812-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed
US-5210193-A Bactericide AMERICAN CYANAMID COMPANY (US) 1993-05-11 US disclosed
US-4965273-A Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents BRISTOL-MYERS COMPANY (US) 1990-10-23 US disclosed
US-4940710-A 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids AMERICAN CYANAMID COMPANY (US) 1990-07-10 US disclosed
US-4886810-A ANTIBACTERIAL DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1989-12-12 US disclosed
JP-S6470483-A QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE HOKURIKU PHARMACEUTICAL 1989-03-15 JP disclosed
JP-S6470484-A QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE HOKURIKU PHARMACEUTICAL 1989-03-15 JP disclosed
CN-87106925-A Naphthyridine and quinoline-carboxylic acid antibacterial agents that the 1-tertiary alkyl replaces 1988-09-14 CN disclosed
CN-87103138-A New quinoline and preparation method thereof 1987-11-04 CN disclosed
EP-0230053-A2 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids AMERICAN CYANAMID COMPANY (US) 1987-07-29 EP disclosed